The historical rank and industry rank for Viridian Therapeutics's OCF Margin % or its related term are showing as below:
STU:1S1'
s OCF Margin % Range Over the Past 10 Years
Min: -76926.82 Med: -1325.17 Max: -216.69
Current: -432.3
During the past 13 years, the highest OCF Margin % of Viridian Therapeutics was -216.69%. The lowest was -76926.82%. And the median was -1325.17%.
STU:1S1's OCF Margin % is ranked worse than 71.01% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs STU:1S1: -432.30
Viridian Therapeutics OCF Margin % Related Terms
Viridian Therapeutics OCF Margin % Historical Data
* Premium members only.
The historical data trend for Viridian Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1S1 vs SION, NTLA, STOK: OCF Margin % Comparison
For the Biotechnology subindustry, Viridian Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viridian Therapeutics OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (STU:1S1) has a OCF Margin % of -84,836.89% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Viridian Therapeutics and its competitors. According to the industry distribution chart, Viridian Therapeutics ranks #681 out of 959 companies in the Biotechnology industry, placing it in the top 71%.
Is Viridian Therapeutics' OCF Margin % too high?
Viridian Therapeutics' current OCF Margin % is -84,836.89%. Based on the distribution chart, Viridian Therapeutics ranks #681 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viridian Therapeutics has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' OCF Margin % compare to SION and NTLA?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #681 out of 959 companies for OCF Margin %. This places Viridian Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current OCF Margin % is -84,836.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Viridian Therapeutics (STU:1S1) is currently considered Possible Value Trap. The stock's GF Value™ is €1,489.40, compared to a current price of €15.70 — trading 98.9% below its estimated fair value. The current OCF Margin % is -84,836.89%. Viridian Therapeutics' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current OCF Margin % is -84,836.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viridian Therapeutics (STU:1S1) Overvalued in 2026?
Based on GuruFocus' analysis, Viridian Therapeutics stock appears to be undervalued.
The current stock price of €15.70 is trading 98.9% below its estimated GF Value™ of €1,489.40.
GuruFocus considers Viridian Therapeutics to be Possible Value Trap.
Key valuation signals for STU:1S1:
OCF Margin %: -84,836.89%
GF Value™: €1,489.40 vs. price of €15.70 (98.9% below fair value)
No single metric tells the full story. See the STU:1S1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
60GF Score
Get the complete analysis for STU:1S1
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1S1 has been successfully added to your 
